BioSpace News Archive

Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company’s common stock.

CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, issues a stockholder letter from Chief Executive Officer, Dr. Phillip Chan.

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that it will be participating in the following upcoming investor conferences

Generation Bio Co., an innovative genetic medicines company creating a new class of gene therapy, announced that Ron Cooper has been appointed to its Board of Directors.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021.

Intellia Therapeutics, Inc., a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its fourth quarter and full-year 2020 financial results and operational highlights in a conference call on February 25, 2021 at 8 a.m. ET.

Translate Bio announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the SVB Leerink Virtual 10th Annual Global Healthcare Conference on Friday, February 26, 2021 at 9:20 a.m. EST.

Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces publication of two pivotal studies that provided the basis for approval of Leukine (sargramostim, yeast-derived rhu GM-CSF) to improve survival in patients expoed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).

GenesisCare — one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom — today announced the addition of the new Elekta Versa HD™ at its Asheville location.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its fourth quarter and full year 2020 financial results will be released after the market closes on Thursday, February 25, 2021